In vitro evaluation of bevacizumab toxicity on a retinal ganglion cell line

Acta Ophthalmologica

Volumn 87, Issue 6, 2009, Pages 618-622

  Sharma, Rajesh K ^a   Chalam, Kakarla V ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Bevacizumab; Ganglion cells; Neovascularization; VEGF

Indexed keywords

BEVACIZUMAB; BOVINE SERUM ALBUMIN; BROXURIDINE; CRYSTAL VIOLET; PROPIDIUM IODIDE;

ARTICLE; CELL COUNT; CELL GROWTH; CELL LINE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; DRUG SCREENING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN CONTENT; RETINA GANGLION CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; BROMODEOXYURIDINE; CATTLE; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FETAL BLOOD; OSMOLAR CONCENTRATION; RATS; RETINAL GANGLION CELLS; SERUM ALBUMIN, BOVINE;

EID: 69449100517     PISSN: 1755375X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2008.01410.x     Document Type: Article

References (15)

1. Aggio FB, Farah ME, Silva WC Melo GB (2007 Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments. Graefes Arch Clin Exp Ophthalmol 245 : 215 220.
2. Algvere PV, Steen B, Seregard S Kvanta A (2008 A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. Acta Ophthalmol 86 : 482 489.
3. Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, Paschke M, Zahn G Cursiefen C (2007 Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 48 : 2545 2552.
4. Donahue ML, Phelps DL, Watkins RH, LoMonaco MB Horowitz S (1996 Retinal vascular endothelial growth factor (VEGF) mRNA expression is altered in relation to neovascularization in oxygen-induced retinopathy. Curr Eye Res 15 : 175 184.
5. Hashimoto T, Zhang XM, Chen BY Yang XJ (2006 VEGF activates divergent intracellular signalling components to regulate retinal progenitor cell proliferation and neuronal differentiation. Development 133 : 2201 2210.
6. Iriyama A, Chen YN, Tamaki Y Yanagi Y (2007 Effect of anti-VEGF antibody on retinal ganglion cells in rats. Br J Ophthalmol 91 : 1230 1233.
7. Kernt M, Neubauer AS Kampik A (2007 Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure. Acta Ophthalmol Scand 85 : 119 120. (Pubitemid 46140172)
8. Kilic U, Kilic E, Jarve A et al. (2006 Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERK-1/2 and Akt pathways. J Neurosci 26 : 12439 12446.
9. Kim H, Fariss RN, Zhang C, Robinson SB, Thill M Csaky KG (2008 Mapping of the neonatal Fc receptor in the rodent eye. Invest Ophthalmol Vis Sci 49 : 2025 2029.
10. Sandercoe TM, Geller SF, Hendrickson AE, Stone J Provis JM (2003 VEGF expression by ganglion cells in central retina before formation of the foveal depression in monkey retina: evidence of developmental hypoxia. J Comp Neurol 462 : 42 54.
11. Sjostrand J, Karlsson JO Andersson AK (1992 Changes in the soluble protein of the human vitreous in vitreoretinal disease. Acta Ophthalmol (Copenh) 70 : 814 819.
12. Spitzer MS, Wallenfels-Thilo B, Sierra A, Yoeruek E, Peters S, Henke-Fahle S, Bartz-Schmidt KU Szurman P (2006 Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol 90 : 1316 1321.
13. Tanaka E, Aoyama J, Miyauchi M, Takata T, Hanaoka K, Iwabe T Tanne K (2005 Vascular endothelial growth factor plays an important autocrine/paracrine role in the progression of osteoarthritis. Histochem Cell Biol 123 : 275 281.
14. Waldmann TA (2003 Immunotherapy: past, present and future. Nat Med 9 : 269 277.
15. Wolkers WF, Tablin F Crowe JH (2002 From anhydrobiosis to freeze-drying of eukaryotic cells. Comp Biochem Physiol A Mol Integr Physiol 131 : 535 543.